Press Releases Items Per Page 102550 Year None2020201920182017201620152014 02-06-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 02-05-2020 Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference 01-30-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule 01-15-2020 Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update 01-13-2020 Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive
02-06-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
01-15-2020 Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
01-13-2020 Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive
